Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
Complete Title: A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF 07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS
Trial Phase: I
Investigator: Rafael Santana-Davila
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic and potential clinical benefit of PF-07257876, a CD47-PD-L1 bispecific antibody, in participants with selected advanced or metastatic tumors for whom no standard therapy is available. The study contains 2 parts, single agent Dose Escalation (Part 1) to determine the recommended dose of PF-07257876, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose.
Keywords:
- Ovarian Cancer
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Carcinoma, Squamous Cell
- Neoplasms, Squamous Cell
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Rafael Santana-Davila
RG1121636
NCT04881045
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF 07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS
Ovarian Cancer
Lung Carcinoma, Non-Small-Cell (NSCLC)
Carcinoma, Squamous Cell
Neoplasms, Squamous Cell